JP2024542939A - 抗体及びその使用方法 - Google Patents

抗体及びその使用方法 Download PDF

Info

Publication number
JP2024542939A
JP2024542939A JP2024522269A JP2024522269A JP2024542939A JP 2024542939 A JP2024542939 A JP 2024542939A JP 2024522269 A JP2024522269 A JP 2024522269A JP 2024522269 A JP2024522269 A JP 2024522269A JP 2024542939 A JP2024542939 A JP 2024542939A
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
antigen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542939A5 (https=
Inventor
ミケーレ フィチェラ
リン ヤン
ジュチュン ウー
ヒレン パテル
フワ ワン
Original Assignee
リジェネクスバイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リジェネクスバイオ インコーポレイテッド filed Critical リジェネクスバイオ インコーポレイテッド
Publication of JP2024542939A publication Critical patent/JP2024542939A/ja
Publication of JP2024542939A5 publication Critical patent/JP2024542939A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2878—Muscular dystrophy
    • G01N2800/2885—Duchenne dystrophy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024522269A 2021-10-15 2022-10-15 抗体及びその使用方法 Pending JP2024542939A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256511P 2021-10-15 2021-10-15
US63/256,511 2021-10-15
PCT/US2022/078180 WO2023064947A1 (en) 2021-10-15 2022-10-15 Antibodies and methods of using thereof

Publications (2)

Publication Number Publication Date
JP2024542939A true JP2024542939A (ja) 2024-11-19
JP2024542939A5 JP2024542939A5 (https=) 2025-10-22

Family

ID=84331799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522269A Pending JP2024542939A (ja) 2021-10-15 2022-10-15 抗体及びその使用方法

Country Status (6)

Country Link
US (1) US20240425572A1 (https=)
EP (1) EP4415822A1 (https=)
JP (1) JP2024542939A (https=)
CA (1) CA3234162A1 (https=)
IL (1) IL311963A (https=)
WO (1) WO2023064947A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026006341A1 (en) 2024-06-24 2026-01-02 Regenxbio Inc. Microdystrophin gene therapy administration for treatment of dystrophinopathies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
US20080187954A1 (en) 2004-03-10 2008-08-07 Lonza Ltd. Method For Producing Antibodies
CA2581208A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
EP2238154B1 (en) 2008-01-18 2015-09-16 Bio-Rad Laboratories, Inc. Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TWI908746B (zh) 2019-11-28 2025-12-21 美商銳進科斯生物股份有限公司 微小肌縮蛋白基因療法之構築體及其用途
US20240003898A1 (en) * 2020-10-30 2024-01-04 Pfizer Inc. Methods for measuring dystrophin in tissue samples

Also Published As

Publication number Publication date
US20240425572A1 (en) 2024-12-26
IL311963A (en) 2024-06-01
EP4415822A1 (en) 2024-08-21
CA3234162A1 (en) 2023-04-20
WO2023064947A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
US20230228772A1 (en) Methods For Detecting Phosphorylated Alpha-Synuclein
JP3105898B2 (ja) 組換えｄｎａタンパクの製造方法
US20240043498A1 (en) Glycoprotein hormone receptor mutations
CN110366558A (zh) 针对泛素c末端水解酶l1(uch-l1)和胶质纤维酸性蛋白(gfap)的抗体及相关方法
JP7692404B2 (ja) 多重特異性抗原結合分子を含む組成物における不純物分子の分析方法
Qiu et al. Engineering an anti-CD52 antibody for enhanced deamidation stability
KR20210035249A (ko) Ns1 단백질의 결합 단백질
Ragunathan et al. Metal binding is critical for the folding and function of laminin binding protein, Lmb of Streptococcus agalactiae
US20240425572A1 (en) Antibodies and methods of using thereof
Ali et al. Development of monoclonal antibodies against recombinant LipL21 protein of pathogenic Leptospira through phage display technology
Killer et al. Cryo-EM structure of an atypical proton-coupled peptide transporter: di-and tripeptide permease C
Nylander et al. Structural and functional analysis of the N-terminal domain of the Streptococcus gordonii adhesin Sgo0707
KR102785236B1 (ko) 항 인간 심근 트로포닌 i의 항체 및 그 사용
Hollinger et al. Expression and purification of the mitochondrial transmembrane protein FAM210A in Escherichia coli
Kinoshita et al. Protein purification and preliminary crystallographic analysis of human Lyn tyrosine kinase
WO2015044083A1 (en) Thermus thermophilus slyd fkbp domain specific antibodies
Thongkum et al. Comparative evaluation of E. coli expression systems for soluble hScFv-IL-17A with an unpaired CDR-L3 cysteine
Markússon et al. High-affinity nanobodies as tools for structural and functional studies on mammalian Arc
KR20240113649A (ko) 항-베타 아밀로이드 항체 및 이의 용도
EP4705556A2 (en) High throughput fab antibody fragment generation and ranking
JP2024059658A (ja) 安定性及び生産力価を向上させるためのモノクローナル抗体操作
KR20240113650A (ko) 항-타우 단백질 항체 및 이의 용도
HK40075206A (en) Analysis method for impurity molecules in composition containing multi specific antigen binding molecules
HK40060315A (en) Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
HK1257103B (en) Methods for detecting phosphorylated alpha-synuclein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251014